GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL328 processing
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Sep 30, 2016

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-16-000246Insurance
Cash60thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.cash

$812.8M · CORE · VALID

Policy-benefit growth64thOwn-history percentile · N=11
Evidence method

Yoy · gp.insurance.policy_benefits

37.47% · OPTIONAL · VALID

Net-income growth20thOwn-history percentile · N=10
Evidence method

Yoy · gp.fundamentals.net_income

-107.63% · CORE · VALID

Premium growth64thOwn-history percentile · N=11
Evidence method

Yoy · gp.insurance.premiums

52.74% · CORE · VALID

Revenue growth100thOwn-history percentile · N=11
Evidence method

Yoy · gp.fundamentals.revenue

396.25% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Decreased
Previous
$1.5B
Current
$812.8M
Delta
-$734.2M
Claims Growth Increased
Previous
7.57%
Current
37.47%
Delta
29.89%
Earnings Growth Decreased
Previous
-82.25%
Current
-107.63%
Delta
-25.38%
Premium Growth Increased
Previous
14.16%
Current
52.74%
Delta
38.58%
Revenue Growth Increased
Previous
24.65%
Current
396.25%
Delta
371.60%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.